The dust-up involving Dr. Charles Nemeroff and Dr. Thomas Insell, director of NIMH shines a light on NIH leaders whose failure to enforce federal disclosure requirements is brushed off with excuses so untenable they have the ring of theater of the absurd. Continue reading →
ACNP
AHRP Letter to Harvard Re: Dr. Biederman’s Research
AHRP proposes a multi-disciplinary team of independent scientists to review ALL of Dr. Joseph Biederman’s publications and supporting documents, including: research protocols, consent forms, and the original (of course, anonymized) data sets with associated code books for all pediatric studies. Continue reading →
Letter of Complaint Re: FDA Double Agent
A follow-up letter to FDA Commissioner, Andrew vonEschenbach RE: Thomas Laughren, FDA’s ‘s Director of Psychiatry Products who has been actively promoting psychotropic drugs–even penning his name to ghostwritten industry-sponsored articles and consensus panels. Continue reading →
Psychiatry News: High Cost of Nondisclosure
Legislation is needed to ensure that conflicts of interest rules in medicine are enforced. One method for reigning in the abuse is to prohibit government grant awards to any researcher who violates financial conflict of interest rules.
20% Drop in Psych Drugs Prescribed for US Children – WashPost
20% Drop in Psych Drugs Prescribed for US Children – WashPost Sat, 8 Oct 2005 The Washington Post reports (below) that prescriptions for antidepressants for children have dropped an unprecedented 20% in the US. A continuing series of substantiated reports and Black . . . Continue reading →
Advisory Committee tells FDA: strengthen warnings on SSRI drug labels now
Advisory Committee tells FDA: strengthen warnings on SSRI drug labels now Wed, 4 Feb 2004 On February 2, more than 60 families and children from all across America testified at a public FDA advisory committee hearing describing (in 2 minutes) how their . . . Continue reading →
Leading ADHD Researcher Blows Whistle on Concerta & CHADD
Leading ADHD Researcher Blows Whistle on Concerta & CHADD Fri, 3 Dec 2004 A newly released report by the Center for Disease Control – Health US 2004–reveals how effective the pharmaceutical industry is in marketing its drugs – whether or not they . . . Continue reading →
FDA’s Double Standard Re: Advisory Committee Membership
FDA’s Double Standard Re: Advisory Committee Membership Mon, 15 Nov 2004 FDA’s inexplicable actions–the latest being the removal of Dr. Curt Furberg from an FDA advisory committee for alleged "intellectual conflict of interest" – demonstrate hypocracy and intellectual dishonesty. Dr. Furberg independently . . . Continue reading →
Ex-NIH Director Lifted conflict of interest rules, Now favors limits on Drug-Company Ties – LAT
Ex-NIH Director Lifted conflict of interest rules, Now favors limits on Drug-Company Ties – LAT Sun, 14 Mar 2004 Former Director of the National Institutes of Health, Harold Varmus, MD, appeared before a blue ribbon panel convened by his former agency, ostensibly . . . Continue reading →
Infomail Archive
Infomail 2004 News Stories on Human Research Protection and Commentary by Vera Hassner Sharav Dec 31: FDA to review “missing” drug company documents Dec 30: Family of Woman Killed by AIDS Drug Test Sues Doctors, Manufacturer Dec 30: Doctors, Too, Ask: Is . . . Continue reading →
Featured News
AHRP Speaks Out AHRP Press Briefing 9/14/04: Antidepressants & suicide-related risks for children Open Letter to NIMH re Prozac & Concealed Suicide Attempts Open Letter to Officials at NIMH AHRP Briefing 2/2/04: Scientists present suicide evidence Conflicts of Interest policy – New . . . Continue reading →
Statement by Vera Hassner Sharav, President AHRP: 2/2/04 Press Briefing
THE ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) 142 West End Ave. Suite 28P, New York, NY 10023 Tel. No: 212-595-8974, Fax No: 212-595-9086 ***PRESS BRIEFING 2/2/04*** Statement by Vera Hassner Sharav, President, AHRP The Alliance for Human Research Protection is convening this . . . Continue reading →